These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35754226)

  • 1. [Expert consensus on off-label use of small molecule anti-angiogenic drugs in the treatment of metastatic breast cancer].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):523-530. PubMed ID: 35754226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer.
    Bajbouj K; Qaisar R; Alshura MA; Ibrahim Z; Alebaji MB; Al Ani AW; Janajrah HM; Bilalaga MM; Omara AI; Abou Assaleh RS; Saber-Ayad MM; Elmoselhi AB
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraising antiangiogenic therapy for breast cancer.
    Kerbel RS
    Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H
    Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.
    Cheng K; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(13):2540-2564. PubMed ID: 32407259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor therapy in breast cancer.
    Kristensen TB; Knutsson ML; Wehland M; Laursen BE; Grimm D; Warnke E; Magnusson NE
    Int J Mol Sci; 2014 Dec; 15(12):23024-41. PubMed ID: 25514409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles.
    Shashni B; Nishikawa Y; Nagasaki Y
    Biomaterials; 2021 Feb; 269():120645. PubMed ID: 33453633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated patent review of VEGFR-2 inhibitors (2017-present).
    Farghaly TA; Al-Hasani WA; Abdulwahab HG
    Expert Opin Ther Pat; 2021 Nov; 31(11):989-1007. PubMed ID: 34043477
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-angiogenesis in cancer therapeutics: the magic bullet.
    Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenic role of miR-20a in breast cancer.
    Luengo-Gil G; Gonzalez-Billalabeitia E; Perez-Henarejos SA; Navarro Manzano E; Chaves-Benito A; Garcia-Martinez E; Garcia-Garre E; Vicente V; Ayala de la Peña F
    PLoS One; 2018; 13(4):e0194638. PubMed ID: 29617404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1063-1077. PubMed ID: 33342166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for metastatic breast cancer: current status and future directions.
    Chan A
    Drugs; 2009; 69(2):167-81. PubMed ID: 19228074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
    Raben D; Helfrich B
    Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.
    Jiang D; Xu T; Zhong L; Liang Q; Hu Y; Xiao W; Shi J
    Eur J Med Chem; 2023 Sep; 257():115535. PubMed ID: 37285684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asiatic acid inhibits angiogenesis and vascular permeability through the VEGF/VEGFR2 signaling pathway to inhibit the growth and metastasis of breast cancer in mice.
    Tian M; Chen K; Huang J; Chu D; Li J; Huang K; Ma C
    Phytother Res; 2021 Nov; 35(11):6389-6400. PubMed ID: 34541711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.